Symphogen is a clinical-stage antibody oncology focused company with a differentiated product pipeline and significant commercial opportunities.  Inspired by nature, led by science and driven by people, we passionately strive to make that discovery that may have great effect on the lives of patients, their families, and their caregivers. Based on our monoclonal antibody (mAb) research platform, we create differentiated mAb and mAb mixture products candidates. Our pre-clinical and clinical pipeline is well suited for a precision-medicine approach by addressing well-defined, biomarker-selected patient populations. We are headquartered in Denmark with operations in the US.

Biotechnology

Symphogen

Christophe Thurieau

Heidi Rønnest

Malin Carlsson

Michael Herbst

Mads Laustsen

Ivan Horak

Rikke Bolding Jensen

Michael Rasmussen

Scientific Team

Laboratory Team

Leadership Team

Senior Management Team

Management and Operational Support

Information Technology